TY - JOUR
T1 - Leucine-Rich Glioma-Inactivated 1 versus Contactin-Associated Protein-like 2 Antibody Neuropathic Pain
T2 - Clinical and Biological Comparisons
AU - Ramanathan, Sudarshini
AU - Tseng, Mandy
AU - Davies, Alexander J.
AU - Uy, Christopher E.
AU - Paneva, Sofija
AU - Mgbachi, Victor C.
AU - Michael, Sophia
AU - Varley, James A.
AU - Binks, Sophie
AU - Themistocleous, Andreas C.
AU - Fehmi, Janev
AU - Anziska, Yaacov
AU - Soni, Anushka
AU - Hofer, Monika
AU - Waters, Patrick
AU - Brilot, Fabienne
AU - Dale, Russell C.
AU - Dawes, John
AU - Rinaldi, Simon
AU - Bennett, David L.
AU - Irani, Sarosh R.
N1 - Publisher Copyright: © 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
PY - 2021/10
Y1 - 2021/10
N2 - Pain is a under-recognized association of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibodies. Of 147 patients with these autoantibodies, pain was experienced by 17 of 33 (52%) with CASPR2- versus 20 of 108 (19%) with LGI1 antibodies (p = 0.0005), and identified as neuropathic in 89% versus 58% of these, respectively. Typically, in both cohorts, normal nerve conduction studies and reduced intraepidermal nerve fiber densities were observed in the sampled patient subsets. In LGI1 antibody patients, pain responded to immunotherapy (p = 0.008), often rapidly, with greater residual patient-rated impairment observed in CASPR2 antibody patients (p = 0.019). Serum CASPR2 antibodies, but not LGI1 antibodies, bound in vitro to unmyelinated human sensory neurons and rodent dorsal root ganglia, suggesting pathophysiological differences that may underlie our clinical observations. ANN NEUROL 2021;90:683–690.
AB - Pain is a under-recognized association of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibodies. Of 147 patients with these autoantibodies, pain was experienced by 17 of 33 (52%) with CASPR2- versus 20 of 108 (19%) with LGI1 antibodies (p = 0.0005), and identified as neuropathic in 89% versus 58% of these, respectively. Typically, in both cohorts, normal nerve conduction studies and reduced intraepidermal nerve fiber densities were observed in the sampled patient subsets. In LGI1 antibody patients, pain responded to immunotherapy (p = 0.008), often rapidly, with greater residual patient-rated impairment observed in CASPR2 antibody patients (p = 0.019). Serum CASPR2 antibodies, but not LGI1 antibodies, bound in vitro to unmyelinated human sensory neurons and rodent dorsal root ganglia, suggesting pathophysiological differences that may underlie our clinical observations. ANN NEUROL 2021;90:683–690.
UR - https://www.scopus.com/pages/publications/85113737047
U2 - 10.1002/ana.26189
DO - 10.1002/ana.26189
M3 - Article
C2 - 34370313
SN - 0364-5134
VL - 90
SP - 683
EP - 690
JO - Annals of Neurology
JF - Annals of Neurology
IS - 4
ER -